In addition to the huge news of an FDA approval of the first treatment for COVID-19 (Gilead Science’s antiviral IV drug remdesivir), we’re looking at the FDA approval of the first treatment for Ebola, as well as a novel microneedle-based skin patch.
As the FDA continues to develop evolving guidelines, our industry has experienced a sudden, paradigm shift towards hybrid and virtual trials, with telemedicine becoming the “norm” for patient interaction across a variety of therapeutic areas.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.